Clinical trials: Anaplastic Astrocytoma
Brain and Central Nervous System Tumors, Metastatic Cancer
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers
RATIONALE: Radiolabeled monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002752
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Sponsor
- Duke University
Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma.
- Trial name
- NCT03528642
- Testing
- Questionnaire Administration, Radiation Therapy, Telaglenastat Hydrochloride
- Where
- 25 sites in United States
- Volunteers
- 23 people
- Sponsor
- National Cancer Institute (NCI)
Anaplastic Glioma of Brain, Glioblastoma Multiforme
6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients
The goal of this clinical research study is to learn if the combination of 6-Thioguanine, Xeloda (capecitabine), and Celebrex (celecoxib) with Temodar (temozolomide) or Lomustine (CCNU) is effective in the treatment of recurrent…
- Conditions
- Anaplastic Glioma of Brain, Glioblastoma Multiforme, Brain Cancer
- Trial name
- NCT00504660
- Testing
- Capecitabine, Celecoxib (Celebrex), Temozolomide
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- M.D. Anderson Cancer Center
Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS)
Phase I Study of APX005M in Pediatric Central Nervous System Tumors
This phase I trial studies the side effects and best dose of APX005M in treating younger patients with primary malignant central nervous system tumor that is growing, spreading, or getting worse (progressive), or newly diagnosed…
- Conditions
- Glioblastoma Multiforme, High-grade Astrocytoma Not Otherwise Specified (NOS), CNS Primary Tumor, Not Otherwise Specified (NOS), Ependymoma, Not Otherwise Specified (NOS)
- Trial name
- NCT03389802
- Testing
- APX005M treatment for recurrent or refractory primary malignant CNS tumor patients, APX005M treatment for newly diagnosed DIPG patients
- Where
- 11 sites in United States
- Volunteers
- 32 people
- Sponsor
- Pediatric Brain Tumor Consortium
Neurofibromatosis 1 (NF1)
Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma
This is a phase 2, open label, parallel multi-arm study of mirdametinib in combination with radiation in participants with recurrent sporadic glioblastoma (GBM) harboring NF1 alterations (Cohort 1); participants with NF1 with a…
- Trial name
- NF118 (NCT07521657)
- Testing
- mirdametinib with radiation, mirdametinib
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- University of Alabama at Birmingham
Cancer, All Types, Cancer of Liver
The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)
The PIONEER Initiative stands for Precision Insights On N-of-1 Ex vivo Effectiveness Research. The PIONEER Initiative is designed to provide access to functional precision medicine to any cancer patient with any tumor at any…
- Conditions
- Cancer, All Types, Cancer of Liver, Cancer of Stomach, Cancer of Head and Neck
- Trial name
- PIONEER (NCT03896958)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- SpeciCare
Neoplasms, High Grade Glioma
HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma
This study is a clinical trial to assess the efficacy and confirm the safety of intratumoral inoculation of G207 (an experimental virus therapy) combined with a single 5 Gy dose of radiation in recurrent/progressive pediatric…
- Conditions
- Neoplasms, High Grade Glioma, Glioblastoma Multiforme, Malignant Glioma of Brain
- Trial name
- NCT04482933
- Testing
- Biological G207
- Where
- 5 sites in United States
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors, Metastatic Cancer
Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors
RATIONALE: Photodynamic therapy uses light and photosensitizing drugs to kill tumor cells and may be an effective treatment for refractory brain tumors.
- Trial name
- NCT00002647
- Testing
- verteporfin, conventional surgery
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Medical College of Wisconsin
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma
- Trial name
- NCT06333899
- Testing
- Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital
Teratoid Tumor, Atypical, Choroid Plexus Neoplasms
p28 in Treating Younger Patients With Recurrent or Progressive Central Nervous System Tumors
This phase I trial studies the side effects and best dose of azurin-derived cell-penetrating peptide p28 (p28) in treating patients with recurrent or progressive central nervous system tumors.
- Conditions
- Teratoid Tumor, Atypical, Choroid Plexus Neoplasms, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma
- Trial name
- NCT01975116
- Testing
- azurin-derived cell-penetrating peptide p28
- Where
- 11 sites in United States
- Volunteers
- 18 people
- Sponsor
- Pediatric Brain Tumor Consortium
Anaplastic Astrocytoma, Brain Stem Glioma
Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas
This phase I/II trial studies the side effects and the best dose of veliparib when given together with radiation therapy and temozolomide and to see how well they work in treating younger patients newly diagnosed with diffuse…
- Conditions
- Anaplastic Astrocytoma, Brain Stem Glioma, Childhood Mixed Glioma, Fibrillary Astrocytoma
- Trial name
- NCT01514201
- Testing
- 3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, Laboratory Biomarker Analysis
- Where
- 12 sites in United States
- Volunteers
- 66 people
- Sponsor
- National Cancer Institute (NCI)
Glioblastoma Multiforme, Anaplastic Astrocytoma
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after…
- Conditions
- Glioblastoma Multiforme, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, DIPG
- Trial name
- NCT04295759
- Testing
- INCB7839
- Where
- 11 sites in United States
- Volunteers
- 13 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Taurolidine in Treating Patients With Recurrent or Progressive Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of taurolidine in treating patients who have recurrent or…
- Trial name
- NCT00022360
- Testing
- taurolidine
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain Tumor, Glioblastoma
Vaccination With Dendritic Cells Loaded With Brain Tumor Stem Cells for Progressive Malignant Brain Tumor
This is a single center Phase I study to determine the safety and maximum tolerated dose (MTD) of autologous dendritic cells (DCs) loaded with allogeneic brain tumor stem cells administered as a vaccination in children and adults…
- Conditions
- Brain Tumor, Glioblastoma, Medulloblastoma, Ependymoma
- Trial name
- NCT01171469
- Testing
- Dendritic Cells, Imiquimod
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Brain and Central Nervous System Tumors
Monoclonal Antibody Therapy in Treating Patients With Recurrent Gliomas
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00002753
- Testing
- iodine I 131 monoclonal antibody 81C6
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Duke University
Pediatric Brain Tumor, Diffuse Intrinsic Pontine Glioma
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
This research study involves an investigational product: Ad-RTS-hIL-12 given with veledimex for production of human IL-12. IL-12 is a protein that can improve the body's natural response to disease by enhancing the ability of the…
- Trial name
- NCT03330197
- Testing
- Ad-RTS-hIL-12, Oral Veledimex - Arm 1 (Pediatric Brain Tumor), Oral Veledimex - Arm 2 (DIPG)
- Where
- 3 sites in United States
- Volunteers
- 6 people
- Sponsor
- Alaunos Therapeutics
Medulloblastoma, Glioblastoma Multiforme
A Pilot Study of SurVaxM in Children Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma
Patients will receive a vaccine called SurVaxM on this study. While vaccines are usually thought of as ways to prevent diseases, vaccines can also be used to treat cancer.
- Conditions
- Medulloblastoma, Glioblastoma Multiforme, Anaplastic Astrocytoma, High-grade Astrocytoma NOS
- Trial name
- NCT04978727
- Testing
- SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years, SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years, SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
- Where
- 14 sites in United States, Canada
- Volunteers
- 35 people
- Sponsor
- Children's Oncology Group
Glioma, Glioblastoma Multiforme
Genetic Analysis of Brain Tumors
This study will analyze tissue and blood samples from patients with gliomas (a type of brain tumor) to develop a new classification system for these tumors.
- Conditions
- Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma, Oligodendroglioma
- Trial name
- NCT00031538
- Where
- 3 sites in United States
- Volunteers
- 674 people
- Sponsor
- National Cancer Institute (NCI)
Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma
Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors
This phase I trial studies the side effects and best dose of palbociclib isethionate in treating younger patients with central nervous system tumors that have grown, come back, or not responded to treatment.
- Conditions
- Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma
- Trial name
- NCT02255461
- Testing
- palbociclib isethionate, pharmacological study, laboratory biomarker analysis
- Where
- 11 sites in United States
- Volunteers
- 35 people
- Sponsor
- Pediatric Brain Tumor Consortium
Neoplasms, Brain, Glioblastoma Multiforme
HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors
This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor.
- Conditions
- Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum, Neoplasms
- Trial name
- NCT03911388
- Testing
- G207
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- M.D. Anderson Cancer Center